In Vitro Growth of Mobilized Peripheral Blood Progenitor Cells is Significantly Enhanced by Stem Cell Factor

Cesana, Clara; Carlo‐Stella, Carmelo; Mangoni, L; Regazzi, Ester; Garau, D.; Sammarelli, Gabriella; Caramatti, Cecilia; Almici, Camillo; Rizzoli, Vittorio

doi:10.1002/stem.150207

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mobilization by chemotherapy might be ascribed to the recruitment of bone marrow stem cells into proliferation (Danova & Aglietta, 1997) with subsequent egress to the peripheral blood. Alternatively, chemotherapy damages both the haematopoietic and mesenchymal marrow stem cell compartments (Cesana et al, 1997). Therefore, the quality and quantity of the mobilized stem cells may differ between chemotherapeutic regimens and growth factor-containing regimens.…”

Section: Abstract: Cd34mentioning

confidence: 99%

The phenotypic profile of CD34‐positive peripheral blood stem cells in different mobilization regimens

et al. 2000

View full text Add to dashboard Cite

Summary. The type of regimen used might result in mobilization of phenotypically and functionally different CD34 1 cells. We compared the phenotype of CD34 1 cells in leukapheresis products of three homogeneous groups: I, healthy individuals treated with granulocyte colony-stimulating factor (G-CSF) alone (n 13); II, patients mobilized with G-CSF following chemotherapy (n 16); and III, patients mobilized with G-CSF after high-dose chemotherapeutic pretreatment (n 24). Multiparameter flow cytometry was performed for CD341 subpopulation analysis and focused on adhesion molecules, differentiation markers and megakaryocytic markers relevant for stem cell homing, with special reference to the importance of L-selectin expression. Regimens I and II led to higher numbers of mobilized CD34 subpopulations that were also positive for L-selectin, there was no significant difference between the three regimens. A similar approach for the megakaryocytic CD34 1 population resulted in an even worse quality of regimen III: 5´1% of CD34 1 being CD41 1 /L-selectin 1 compared with 9´2% and 8´9% in regimens I and II respectively. We concluded that the phenotypes of the CD34 1 cells in the G-CSF (group I) and G-CSF±chemotherapy (group II) regimens are similar, whereas the phenotype of the CD34 1 cells mobilized in the high-dose regimen (group III) displayed features that might negatively influence homing of the cells. Future studies will be directed towards regimens that will lead to the mobilization of a higher amount of CD34 1 cells with a phenotypically favourable phenotype.

show abstract

Section: Abstract: Cd34mentioning

confidence: 99%

The phenotypic profile of CD34‐positive peripheral blood stem cells in different mobilization regimens

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Stem cell factor (SCM) selectively controls stem cell self-renewal, proliferation, and differentiation. It synergizes with G-CSF, GM-CSF, IL-3, and IL-11 (10, 1 1) to stimulate various hematopoietic compartments (61).…”

Section: Effects Of Cytokines On Normal Cell Growthmentioning

confidence: 99%

Leukemia Cells and the Cytokine Network

Moqattash

Lutton

1998

Experimental Biology and Medicine

View full text Add to dashboard Cite

The cytokine network plays an important role in the growth and differentiation of normal and leukemic cells. Stimulation of this network, which has positive and negative regulators, results in the induction or inhibition of certain hematopoietic events. A cytokine can have multiple effects on various cell types, and combinations of cytokines with each other or with other exogenous substances produce more pronounced effects than any cytokine or agent individually. The mechanisms by which cytokines affect normal and leukemic cell growth and viability may vary depending on the target cell or the cytokine(s) in question. Diseases such as leukemia may result from abnormalities in the cytokine network or their receptors. Cytokines play a major role in leukemogenesis. Normally, hematopoietic cells require certain cytokines for their viability and growth. When the viability factors are withdrawn, apoptotic cell death naturally occurs. Prevention of programmed cell death by the abnormal production of a cytokine may release the cell from normal growth control leading to malignant transformation. Disregulation of genes for hematopoietic growth factors and their receptors may be one of the events that leads to leukemogenesis through an aberrant autocrine growth mechanism. However, cytokines have been used as therapeutic agents in various ways. Differentiation therapy has been widely investigated and proven effective in certain types of cancer. Gene therapy, where the cytokine cDNA is used to reduce tumorigenicity and/or increase immunogenicity is promising. Another kind of therapy using alkylated growth factors has been under focus. This review summarizes the actions and interactions of cytokines that are related to leukemic cell viability and growth. The use of cytokines as therapeutic agents is also discussed.

show abstract

The phenotypic profile of CD34-positive peripheral blood stem cells in different mobilization regimens

Boer¹,

Dräger²,

Haperen³

et al. 2000

Br J Haematol

View full text Add to dashboard Cite

The type of regimen used might result in mobilization of phenotypically and functionally different CD34(+) cells. We compared the phenotype of CD34(+) cells in leukapheresis products of three homogeneous groups: I, healthy individuals treated with granulocyte colony-stimulating factor (G-CSF) alone (n = 13); II, patients mobilized with G-CSF following chemotherapy (n = 16); and III, patients mobilized with G-CSF after high-dose chemotherapeutic pretreatment (n = 24). Multiparameter flow cytometry was performed for CD34(+) subpopulation analysis and focused on adhesion molecules, differentiation markers and megakaryocytic markers relevant for stem cell homing, with special reference to the importance of L-selectin expression. Regimens I and II led to higher numbers of mobilized CD34(+) cells (mean 468 x 10(6) and 491 x 10(6) CD34(+) cells per leukapheresis procedure respectively) than regimen III (mean 41 x 10(6) CD34(+) cells per leukapheresis procedure). Both the expression of L-selectin and CD54 on CD34(+) cells was significantly lower in group III, as was the percentage of megakaryocytic (CD41(+)) progenitors. A higher percentage of primitive (CD38(-) and/or HLA(-)DR(-)) CD34(+) cells was found in group III, correlating with a higher clonogenicity of the CD34(+) cells. However, when comparing the CD34(+)_ subpopulations that were also positive for L-selectin, there was no significant difference between the three regimens. A similar approach for the megakaryocytic CD34+ population resulted in an even worse quality of regimen III: 5.1% of CD34(+) being CD41(+)/L-selectin(+) compared with 9.2% and 8.9% in regimens I and II respectively. We concluded that the phenotypes of the CD34(+) cells in the G-CSF (group I) and G-CSF-chemotherapy (group II) regimens are similar, whereas the phenotype of the CD34(+) cells mobilized in the high-dose regimen (group III) displayed features that might negatively influence homing of the cells. Future studies will be directed towards regimens that will lead to the mobilization of a higher amount of CD34(+) cells with a phenotypically favourable phenotype.

show abstract

In Vitro Growth of Mobilized Peripheral Blood Progenitor Cells is Significantly Enhanced by Stem Cell Factor

Cited by 3 publications

References 35 publications

The phenotypic profile of CD34‐positive peripheral blood stem cells in different mobilization regimens

The phenotypic profile of CD34‐positive peripheral blood stem cells in different mobilization regimens

Leukemia Cells and the Cytokine Network

The phenotypic profile of CD34-positive peripheral blood stem cells in different mobilization regimens

Contact Info

Product

Resources

About